Trials / Unknown
UnknownNCT05179317
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer
A Phase II Study of QL1706 Plus Chemotherapy With or Without Bevacizumab for the First-Line Treatment of Recurrent, or Metastatic Cervical Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of QL1706 Plus Chemotherapy in Women With Recurrent, or Metastatic Cervical Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QL1706 | Drug: QL1706 Intravenous Infusion Drug: Paclitaxel injection Intravenous Infusion Drug: Cisplatin/Carboplatin Intravenous Infusion Drug:Bevacizumab Intravenous Infusion |
Timeline
- Start date
- 2021-05-30
- Primary completion
- 2022-12-01
- Completion
- 2023-12-01
- First posted
- 2022-01-05
- Last updated
- 2022-07-29
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05179317. Inclusion in this directory is not an endorsement.